Repligen Corporation
$ 134.67
-0.54%
24 Feb - close price
- Market Cap 7,621,767,000 USD
- Current Price $ 134.67
- High / Low $ 139.44 / 120.00
- Stock P/E 13540.00
- Book Value 37.01
- EPS 0.01
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE N/A %
- 52 Week High 175.77
- 52 Week Low 102.97
About
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$190.89
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-11-12 | 2024-07-30 | 2024-05-01 | 2024-02-21 | 2023-10-31 | 2023-08-02 | 2023-05-02 | 2023-02-22 |
| Reported EPS | 0.46 | 0.37 | 0.39 | 0.44 | -0.0117 | 0.33 | 0.28 | 0.33 | 0.23 | 0.53 | 0.64 | 0.68 |
| Estimated EPS | 0.42 | 0.39 | 0.3668 | 0.4191 | 0.33 | 0.33 | 0.3 | 0.33 | 0.17 | 0.48 | 0.59 | 0.58 |
| Surprise | 0.04 | -0.02 | 0.0232 | 0.0209 | -0.3417 | 0 | -0.02 | 0 | 0.06 | 0.05 | 0.05 | 0.1 |
| Surprise Percentage | 9.5238% | -5.1282% | 6.325% | 4.9869% | -103.5455% | 0% | -6.6667% | 0% | 35.2941% | 10.4167% | 8.4746% | 17.2414% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGEN
2026-02-24 15:54:17
Repligen Corp. (RGEN) announced its Q4 2025 financial results, reporting adjusted earnings of 49 cents per share and revenue of $197.9 million, both surpassing analyst expectations. For the full year 2025, the company recorded a profit of $48.9 million on $738.3 million in revenue. Repligen also provided a 2026 outlook, projecting earnings per share between $1.93 and $2.01 and revenue in the range of $810 million to $840 million.
2026-02-24 13:54:17
Repligen Corporation (NASDAQ:RGEN) reported a strong beat on Q4 2025 earnings and revenue, with sales up 18.1% year-over-year and non-GAAP EPS exceeding analyst forecasts. Despite this positive quarterly performance, the stock fell significantly in pre-market trading, down approximately 5%, due to disappointing financial guidance for the full year 2026. The company's revenue forecast of $825 million for 2026 is below the analyst consensus of $840.8 million, suggesting a cautious outlook from management.
2026-02-24 12:54:17
Repligen Corporation announced strong financial results for Q4 and full year 2025, with significant revenue and GAAP net income growth. The company achieved key operational milestones, including new product launches and APAC expansion, and provided optimistic financial guidance for 2026, expecting continued revenue growth and margin expansion.
2026-02-24 12:54:17
Repligen Corp. exceeded analyst expectations for its fourth-quarter earnings, reporting a net profit of $13.3 million and adjusted earnings of $0.49 per share. Quarterly revenue reached $197.9 million, also surpassing estimates. For the upcoming year, the company forecasts annual earnings per share between $1.93 and $2.01 on revenues of $810 million to $840 million.
2026-02-23 19:22:16
Repligen Corporation (RGEN), a healthcare sector player specializing in bioprocessing technologies, shows strong growth momentum and a 40% upside potential according to analyst ratings. Despite a recent stock dip and low Rgen on Equity (ROE), the company's robust revenue growth, strategic innovations, and favorable analyst sentiment with an average target price of $190.89 make it an attractive investment, especially for long-term growth in the bioprocessing space.
2026-02-23 15:17:33
Repligen Corporation is set to release its fourth-quarter 2025 earnings, with investors closely watching for signs of bioprocessing industry recovery. Analysts expect 44 cents per share on $192.89 million in revenue, and believe the stock has a 41% upside from its current price. Key areas of focus for investors include sustained revenue acceleration from order growth, margin expansion driven by new products, and management's forward guidance on the bioprocessing sector's return to historical growth rates.
